China Universal Asset Management Co. Ltd. Acquires 7,597 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

China Universal Asset Management Co. Ltd. lifted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 64.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,421 shares of the company's stock after purchasing an additional 7,597 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in Neurocrine Biosciences were worth $2,238,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in shares of Neurocrine Biosciences by 3.5% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 252,565 shares of the company's stock worth $34,834,000 after acquiring an additional 8,630 shares during the period. Van ECK Associates Corp lifted its position in shares of Neurocrine Biosciences by 1,325.5% in the 1st quarter. Van ECK Associates Corp now owns 92,243 shares of the company's stock worth $12,722,000 after purchasing an additional 85,772 shares during the period. Twin Tree Management LP boosted its stake in shares of Neurocrine Biosciences by 59.4% in the 1st quarter. Twin Tree Management LP now owns 19,147 shares of the company's stock valued at $2,641,000 after purchasing an additional 7,136 shares during the last quarter. Redwood Investment Management LLC acquired a new stake in shares of Neurocrine Biosciences during the first quarter worth $642,000. Finally, Forsta AP Fonden raised its stake in Neurocrine Biosciences by 94.3% during the first quarter. Forsta AP Fonden now owns 34,200 shares of the company's stock worth $4,717,000 after buying an additional 16,600 shares during the last quarter. Institutional investors own 92.59% of the company's stock.

Insider Buying and Selling

In other news, insider Julie Cooke sold 12,632 shares of Neurocrine Biosciences stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $153.26, for a total transaction of $1,935,980.32. Following the completion of the sale, the insider now owns 18,202 shares in the company, valued at approximately $2,789,638.52. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, insider Julie Cooke sold 12,632 shares of the company's stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $153.26, for a total value of $1,935,980.32. Following the completion of the transaction, the insider now directly owns 18,202 shares in the company, valued at approximately $2,789,638.52. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William H. Rastetter sold 14,250 shares of the stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the transaction, the director now directly owns 37,491 shares in the company, valued at approximately $5,499,554.79. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 59,968 shares of company stock worth $8,999,632 over the last ninety days. 4.30% of the stock is owned by corporate insiders.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX traded down $0.01 during trading on Tuesday, hitting $116.19. 1,136,583 shares of the company were exchanged, compared to its average volume of 849,988. Neurocrine Biosciences, Inc. has a 52-week low of $103.63 and a 52-week high of $157.98. The stock has a 50 day moving average of $122.22 and a 200 day moving average of $133.84. The company has a market cap of $11.73 billion, a PE ratio of 34.85 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.15 by ($0.52). The firm had revenue of $590.20 million during the quarter, compared to analysts' expectations of $545.98 million. Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. The business's revenue for the quarter was up 30.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.95 earnings per share. Sell-side analysts forecast that Neurocrine Biosciences, Inc. will post 4.37 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Royal Bank of Canada cut their price target on shares of Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating on the stock in a research report on Friday, October 4th. Barclays decreased their target price on Neurocrine Biosciences from $180.00 to $160.00 and set an "overweight" rating for the company in a research note on Monday, September 9th. Citigroup boosted their price target on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a "neutral" rating in a research note on Friday, August 2nd. Morgan Stanley increased their price target on Neurocrine Biosciences from $160.00 to $170.00 and gave the stock an "overweight" rating in a report on Friday, July 12th. Finally, Robert W. Baird lifted their price objective on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the company an "outperform" rating in a research note on Friday, August 2nd. Five research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Neurocrine Biosciences presently has an average rating of "Moderate Buy" and a consensus target price of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.